RU58841 yakında elimde olacak Türkiyede bunu isteyen kimler var? ( I’ll have RU58841 in hand soon; who in Türkiye is interested in it?)
    Finasteride/Dutasteride 8/2/2026

    From the encyclopedia
    RU58841 →

    Experimental topical anti-androgen sold as a research chemical

    Dutasteride →

    5-alpha reductase inhibitor that blocks both enzyme types, a stronger DHT blocker than finasteride

    Finasteride →

    Popular 5-alpha reductase inhibitor that lowers DHT, taken as a pill or used topically

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    • RU58841 5 grams a few months
    • Dutasteride 2 years
    • Finasteride long period
    the tone is 😀 positive with reduced shedding results.

    Other terms

    The conversation is about sourcing RU58841 in Türkiye, with the original poster sharing their positive experience using it for hair loss, noting it reduced shedding without side effects. They plan to distribute it after lab testing, considering customs and pricing challenges.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community Has anyone seen the data on this 539% boost breakthrough?

       866 upvotes 6 months ago
      Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

      community PP405 Phase 2a press release with early results

       700 upvotes 1 year ago
      PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

      community Lab results from actifolic RU58841

       38 upvotes 3 years ago
      The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

      community How essential is scalp biopsy when dealing with hair loss?

      in Treatment  6 upvotes 1 year ago
      The user experienced hair loss despite using Fin and Min for 12 years and switched to Dutasteride, RU58841, and Keto scalp serum, but shedding and itch persist. They are considering increasing Dutasteride to 2.5mg and questioning the necessity of a scalp biopsy, with mixed opinions on its usefulness.

    Related Research

    6 / 6 results

      research Therapeutic strategies for treating hair loss

      42 citations , March 2006 in “Drug Discovery Today: Therapeutic Strategies”
      This article discusses the need for rational strategies in developing hair loss drugs targeting specific events in hair follicle cycling, reporting no clinical findings but emphasizing the importance of understanding molecular controls.

      research Alcohol and Prostate Cancer: Time to Draw Conclusions

      9 citations , February 2022 in “Biomolecules”
      This review concludes that while many epidemiological studies suggest high alcohol intake is associated with an increased risk of prostate cancer, the evidence may be affected by confounding factors such as diet and lifestyle.

      research E-Poster

      December 2023 in “Indian Journal of Endocrinology and Metabolism”
      In this case report from People's College of Medical Sciences, a 20-year-old man initially misdiagnosed with Addison's disease was ultimately found to have strongyloidiasis, with his symptoms and weight loss improving after antihelminthic treatment.

      research Cutaneous manifestations of systemic infection in children

      May 1993 in “Current problems in dermatology”
      This review discusses diagnostic approaches for childhood skin diseases with fever through clinical observations and covers recent advances in understanding the pathogenesis and epidemiology of related infections, without reporting new clinical results.